At a glance
ClinicalIndex Comparison RecordEarly Ph 1Completed· 12 enrolled
Drug / intervention
Pau d' Arcodietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Arm, Open-label Pilot Trial Examining the Effects of Pau d' Arco on Primary Dysmenorrhea in Reproductive Age Women
In Brief
A Early Phase 1 clinical trial evaluating Pau d' Arco for Primary Dysmenorrhea. Completed, enrolled 12 participants across 1 site.
Detailed Summary
A single arm, open-label trial evaluating safety and tolerability of encapsulated Tabebuia avellanedae in 12 generally healthy women aged 18-45 with primary dysmenorrhea (PDM). This will be the first study evaluating the safety and tolerability of Tabebuia avellanedae in PDM. We also aim to collect proof-of-concept mechanistic data supporting the hypothesis that Tabebuia avellanedae reduces PGE2 concentration in vivo in women with PDM.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Dysmenorrhea
CountriesUnited States
Collaborators--
Timeline
Early Ph 1CompletedFinished
2020202120222023202420252026
Enrollment StartJul 2019
First PostedJan 2020
Primary CompletionJan 2022
Study CompletionDec 2022
TodayJul 2026
First PostedJan 29, 2020
Enrollment StartJul 30, 2019
Primary CompletionJan 1, 2022
Study CompletionDec 15, 2022
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 6.4 years ago
Interventions
Pau d' Arcodietary
Encapsulated herbal Pau d' Arco.